Shots:

• Takeda initiates the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG)- TAK-888 for the treatment of high-risk individuals with COVID-19 and evaluates its marketed and pipeline products as viable candidates for COVID-19
• Takeda is currently working with multiple national health and regulatory agencies in the US- EU- and Asia to expedite the research of TAK-888
• H-IG works by concentrating the pathogen-specific Ab from plasma collected from recovered patients/vaccinated donors in the future. Takeda will initially produce the therapy in a segregated area within its manufacturing facility in Georgia

Click here to­ read full press release/ article 

 Ref: Takeda | Image: Takeda